Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

N/A
1(50.0%)
Phase 4
1(50.0%)
2Total
N/A(1)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT04069494Completed

Descriptors and Predictors of Burden and Information Needs

Role: lead

NCT02922244Not ApplicableCompleted

Effects of Herbal Products on Reduction of Radiation-induced Dermatitis in Breast Cancer Patients

Role: lead

NCT02684942Phase 4Completed

Comparison of Meperidine and Fentanyl on Pain Scale and QOL in Brachytherapy

Role: lead

NCT03106350Completed

Symptoms Experienced and Quality of Life in Breast Cancer Receiving Radiotherapy

Role: lead

All 4 trials loaded